Trellis

Podcast episode

#406 ‒ Migraine, cluster headache, and tension headache: symptoms, causes, prevention, and treatment | Brian Grosberg, M.D.

by Ken Rona · ·The Peter Attia Drive

drug-treatment healthcare medical-innovation medication-safety mental-health

TL;DR

Peter Attia interviews Dr. Brian Grosberg, director of the Hartford Healthcare Headache Program and professor of neurology at UConn, for a detailed clinical tour of migraine, cluster headache, and tension headache. The episode covers diagnosis, hormonal and genetic drivers, lifestyle risk factors, and the full range of treatments from beta blockers to CGRP monoclonal antibodies to neuromodulation devices. If you or someone close to you deals with frequent or disabling headaches, this is substantive and actionable.

What was covered

  • Classifying headaches. Brian Grosberg distinguishes primary headaches (migraine, cluster, tension — conditions in themselves) from secondary headaches (caused by something else, from a brain tumor to caffeine withdrawal to medication overuse). Over 300 types exist; diagnosis rests almost entirely on patient history because there are no reliable biomarkers or imaging findings.

  • Migraine epidemiology and the specialist shortage. Migraine affects roughly 12% of the U.S. population — about 45 million people — with women affected at roughly three times the rate of men (approximately 18% of women). About 1–2% of the population has chronic migraine, meaning headache on 15 or more days per month. Fewer than 50 fellowship-trained headache neurologists complete training annually in the U.S., leaving demand far outpacing supply.

  • Hormonal and genetic drivers. Migraine is polygenic and highly hereditary. Roughly two-thirds of women with migraine notice attacks clustered around menstruation; about 10% experience pure menstrual migraine (attacks only around menses). The key mechanism appears to be the rate of estrogen decline in the late luteal phase, not estrogen deprivation per se. Perimenopause often worsens migraine; about two-thirds of women improve after completing the transition to menopause, but 10–20% do not.

  • The phases of a migraine and the allodynia window. Migraine has four phases: premonitory (yawning, food cravings, neck stiffness — hours before pain), aura (reversible neurologic symptoms, typically visual, in about 25–33% of sufferers), the headache itself, and postdrome ("hungover" feeling lasting hours to a day or two after pain resolves). About 60–70% of migraine sufferers experience allodynia — uncomfortable sensation from normally neutral stimuli such as brushing hair or wearing glasses — typically beginning 30–60 minutes into an attack. Grosberg emphasizes that once allodynia sets in, triptans become less effective, so timing of treatment matters.

  • Lifestyle risk factors that drive frequency. Obesity is a major, underappreciated risk factor: morbidly obese individuals (BMI ≥35) face five times the risk of more frequent migraine; those with BMI 30–35 face roughly double the risk. Other modifiable factors include sleep disturbance (including untreated sleep apnea), mood disorders (depression and anxiety co-occur with migraine at above-chance rates), irregular sleep and meal schedules, caffeine timing variability, and medication overuse. NSAIDs, acetaminophen, triptans, barbiturate-containing analgesics (Fioricet), and opioids, when used two or more days per week regularly, can paradoxically increase headache frequency.

  • Pharmacological prevention. About 40% of migraine sufferers qualify medically for preventive therapy, but only 16–17% actually receive it. Drug classes used for prevention include: beta blockers (propranolol, timolol — FDA approved); tricyclic antidepressants (amitriptyline, nortriptyline — often at sub-antidepressant doses); antiseizure medications (topiramate/Topamax, valproic acid/Depakote); calcium channel blockers (verapamil — used more for cluster headache, sometimes at very high doses); and Botox (onabotulinumtoxinA — FDA approved for chronic migraine, given quarterly via the PREEMPT protocol). Grosberg stresses that none of these carry depression or epilepsy implications for the patient; they are being used for their neurological mechanisms.

  • CGRP-targeted therapies — the biggest advance. Calcitonin gene-related peptide (CGRP) is a neuropeptide released during migraine that is central to pain signaling. CGRP antagonists come in two forms: large monoclonal antibodies (self-injected monthly or infused quarterly) and small-molecule gepants (oral or nasal spray, some approved for both acute and preventive use). Grosberg calls the monoclonal antibodies the biggest change in his clinical practice. About 60% of patients see meaningful benefit, defined as at least 50% reduction in attack frequency; failing one drug in the class does not predict failure in another. Cost is a significant barrier — these drugs cost thousands of dollars annually, and insurance step-therapy requirements often mandate failing two or three conventional treatments first.

  • Acute rescue treatments. Triptans (seven available; sumatriptan/Imitrex was first) remain a cornerstone of acute treatment, working on serotonin receptors. Route matters: injection provides the fastest onset (median ~9 minutes for cluster headache), nasal sprays vary in bioavailability, oral forms are slower but better tolerated. Gepants (e.g., ubrogepant/Ubrelvy, zavegepant/Zavzpret nasal) are newer acute options without the vasoconstriction concerns of triptans. Opioids and barbiturate-containing analgesics are last-resort options given their high potential to cause medication-overuse headache.

Notable claims & predictions

  • Grosberg on obesity and migraine: "People who are morbidly obese are at five times higher risk for more frequent migraine." Even BMI 30–35 roughly doubles the risk. He describes studies showing improvement with both surgical and non-surgical weight loss.

  • Grosberg on the treatment gap: "About 40% of people may be eligible based on indications for migraine prevention, but only like 16 or 17% are actually receiving preventive therapy." The gap is driven by under-recognition by clinicians and insurance barriers.

  • Grosberg on medication overuse: Opioids and barbiturate analgesics (Fioricet), even used "a handful of times per month," carry "a particularly high risk for medication overuse headache" — meaning they can themselves cause the very chronic daily headaches they are meant to treat.

  • Grosberg on CGRP monoclonals: "It doesn't mean that they work for everyone... they probably work for up to 60% or so of patients with migraine." Failing one drug in the class does not predict failure in another, because the antibodies bind to different epitopes.

  • Grosberg on aura vs. stroke: A key distinguishing feature: migraine aura evolves gradually over 5–60 minutes with positive and negative visual phenomena; TIA/stroke symptoms are maximal at onset and usually produce only negative (loss of) vision, not the zigzag or scintillating patterns of aura.

  • Grosberg on cluster headache misdiagnosis: Because cluster attacks peak in January–February and July–August, and involve nasal congestion and eye symptoms, patients are routinely treated for sinus infections (antibiotics) or allergies (shots), or have dental procedures performed, before cluster headache is ever considered.

Fact check

CGRP levels normalize with sumatriptan — supported. Grosberg describes studies showing elevated CGRP during migraine that normalize with sumatriptan treatment. This is well established in the neurological literature and is the mechanistic foundation for the CGRP drug class.

Five times the migraine risk in morbid obesity — plausible but context needed. Grosberg presents this as a solid finding. Population-based research does show a meaningful association between obesity and migraine frequency and chronification; the specific "5x" figure for morbid obesity appears in the literature but the association studies are largely observational, and causality is not established. Weight loss studies showing improvement are real but, as Grosberg himself notes, "not uniformly across the board." The directional claim is reasonable; the precise multiplier should be held with some caution.

50 fellowship-trained headache neurologists per year — plausible, hard to verify. Grosberg states this from direct professional knowledge. The figure is consistent with the known scarcity of accredited headache fellowship programs in the U.S., but the exact annual number is not independently verifiable from the transcript alone.

**Botox (PREEMPT protocol) for chronic migraine

Full analysis

Peter Attia interviews Dr. Brian Grosberg, director of the Hartford Healthcare Headache Program and professor of neurology at UConn, for a detailed clinical tour of migraine, cluster headache, and tension headache. The episode covers diagnosis, hormonal and genetic drivers, lifestyle risk factors, and the full range of treatments from beta blockers to CGRP monoclonal antibodies to neuromodulation devices. If you or someone close to you deals with frequent or disabling headaches, this is substantive and actionable.

What was covered

  • Classifying headaches. Brian Grosberg distinguishes primary headaches (migraine, cluster, tension — conditions in themselves) from secondary headaches (caused by something else, from a brain tumor to caffeine withdrawal to medication overuse). Over 300 types exist; diagnosis rests almost entirely on patient history because there are no reliable biomarkers or imaging findings.

  • Migraine epidemiology and the specialist shortage. Migraine affects roughly 12% of the U.S. population — about 45 million people — with women affected at roughly three times the rate of men (approximately 18% of women). About 1–2% of the population has chronic migraine, meaning headache on 15 or more days per month. Fewer than 50 fellowship-trained headache neurologists complete training annually in the U.S., leaving demand far outpacing supply.

  • Hormonal and genetic drivers. Migraine is polygenic and highly hereditary. Roughly two-thirds of women with migraine notice attacks clustered around menstruation; about 10% experience pure menstrual migraine (attacks only around menses). The key mechanism appears to be the rate of estrogen decline in the late luteal phase, not estrogen deprivation per se. Perimenopause often worsens migraine; about two-thirds of women improve after completing the transition to menopause, but 10–20% do not.

  • The phases of a migraine and the allodynia window. Migraine has four phases: premonitory (yawning, food cravings, neck stiffness — hours before pain), aura (reversible neurologic symptoms, typically visual, in about 25–33% of sufferers), the headache itself, and postdrome ("hungover" feeling lasting hours to a day or two after pain resolves). About 60–70% of migraine sufferers experience allodynia — uncomfortable sensation from normally neutral stimuli such as brushing hair or wearing glasses — typically beginning 30–60 minutes into an attack. Grosberg emphasizes that once allodynia sets in, triptans become less effective, so timing of treatment matters.

  • Lifestyle risk factors that drive frequency. Obesity is a major, underappreciated risk factor: morbidly obese individuals (BMI ≥35) face five times the risk of more frequent migraine; those with BMI 30–35 face roughly double the risk. Other modifiable factors include sleep disturbance (including untreated sleep apnea), mood disorders (depression and anxiety co-occur with migraine at above-chance rates), irregular sleep and meal schedules, caffeine timing variability, and medication overuse. NSAIDs, acetaminophen, triptans, barbiturate-containing analgesics (Fioricet), and opioids, when used two or more days per week regularly, can paradoxically increase headache frequency.

  • Pharmacological prevention. About 40% of migraine sufferers qualify medically for preventive therapy, but only 16–17% actually receive it. Drug classes used for prevention include: beta blockers (propranolol, timolol — FDA approved); tricyclic antidepressants (amitriptyline, nortriptyline — often at sub-antidepressant doses); antiseizure medications (topiramate/Topamax, valproic acid/Depakote); calcium channel blockers (verapamil — used more for cluster headache, sometimes at very high doses); and Botox (onabotulinumtoxinA — FDA approved for chronic migraine, given quarterly via the PREEMPT protocol). Grosberg stresses that none of these carry depression or epilepsy implications for the patient; they are being used for their neurological mechanisms.

  • CGRP-targeted therapies — the biggest advance. Calcitonin gene-related peptide (CGRP) is a neuropeptide released during migraine that is central to pain signaling. CGRP antagonists come in two forms: large monoclonal antibodies (self-injected monthly or infused quarterly) and small-molecule gepants (oral or nasal spray, some approved for both acute and preventive use). Grosberg calls the monoclonal antibodies the biggest change in his clinical practice. About 60% of patients see meaningful benefit, defined as at least 50% reduction in attack frequency; failing one drug in the class does not predict failure in another. Cost is a significant barrier — these drugs cost thousands of dollars annually, and insurance step-therapy requirements often mandate failing two or three conventional treatments first.

  • Acute rescue treatments. Triptans (seven available; sumatriptan/Imitrex was first) remain a cornerstone of acute treatment, working on serotonin receptors. Route matters: injection provides the fastest onset (median ~9 minutes for cluster headache), nasal sprays vary in bioavailability, oral forms are slower but better tolerated. Gepants (e.g., ubrogepant/Ubrelvy, zavegepant/Zavzpret nasal) are newer acute options without the vasoconstriction concerns of triptans. Opioids and barbiturate-containing analgesics are last-resort options given their high potential to cause medication-overuse headache.

Notable claims & predictions

  • Grosberg on obesity and migraine: "People who are morbidly obese are at five times higher risk for more frequent migraine." Even BMI 30–35 roughly doubles the risk. He describes studies showing improvement with both surgical and non-surgical weight loss.

  • Grosberg on the treatment gap: "About 40% of people may be eligible based on indications for migraine prevention, but only like 16 or 17% are actually receiving preventive therapy." The gap is driven by under-recognition by clinicians and insurance barriers.

  • Grosberg on medication overuse: Opioids and barbiturate analgesics (Fioricet), even used "a handful of times per month," carry "a particularly high risk for medication overuse headache" — meaning they can themselves cause the very chronic daily headaches they are meant to treat.

  • Grosberg on CGRP monoclonals: "It doesn't mean that they work for everyone... they probably work for up to 60% or so of patients with migraine." Failing one drug in the class does not predict failure in another, because the antibodies bind to different epitopes.

  • Grosberg on aura vs. stroke: A key distinguishing feature: migraine aura evolves gradually over 5–60 minutes with positive and negative visual phenomena; TIA/stroke symptoms are maximal at onset and usually produce only negative (loss of) vision, not the zigzag or scintillating patterns of aura.

  • Grosberg on cluster headache misdiagnosis: Because cluster attacks peak in January–February and July–August, and involve nasal congestion and eye symptoms, patients are routinely treated for sinus infections (antibiotics) or allergies (shots), or have dental procedures performed, before cluster headache is ever considered.

Fact check

CGRP levels normalize with sumatriptan — supported. Grosberg describes studies showing elevated CGRP during migraine that normalize with sumatriptan treatment. This is well established in the neurological literature and is the mechanistic foundation for the CGRP drug class.

Five times the migraine risk in morbid obesity — plausible but context needed. Grosberg presents this as a solid finding. Population-based research does show a meaningful association between obesity and migraine frequency and chronification; the specific "5x" figure for morbid obesity appears in the literature but the association studies are largely observational, and causality is not established. Weight loss studies showing improvement are real but, as Grosberg himself notes, "not uniformly across the board." The directional claim is reasonable; the precise multiplier should be held with some caution.

50 fellowship-trained headache neurologists per year — plausible, hard to verify. Grosberg states this from direct professional knowledge. The figure is consistent with the known scarcity of accredited headache fellowship programs in the U.S., but the exact annual number is not independently verifiable from the transcript alone.

**Botox (PREEMPT protocol) for chronic migraine

Listen to the episode →

Comments